We can't find the internet
Attempting to reconnect
Something went wrong
Hang in there while we get back on track
£495.00
It has never been this cheap. We have no record of a lower price.
£495 today · cheaper than every other day in the last 3 months
The 2023-2028 Outlook for Antidepressants for Major Depressive Disorders in China
We'll watch every seller, every day. One email when your price arrives.
Price History & Forecast
Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.
Last 87 days · 87 data points (no recent data)
Historical
Generating forecast…
NEW HERE?
Amazon shows you one price. We show you all of them.
Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.
WHAT'S ON THIS PAGE
↑ Price chart
when this has been cheap or pricey
when this has been cheap or pricey
↑ Forecast
where the price is heading next
where the price is heading next
↓ Statistics
all-time high & low, recent range
all-time high & low, recent range
↑ Price alert
name your number, we'll email you
name your number, we'll email you
Price Distribution
Price distribution over 87 days • 1 price levels
Price Analysis
Most common price: £495 (87 days, 100.0%)
Price range: £495 - £495
Price levels: 1 different prices over 87 days
Description
This study covers the latent demand outlook for antidepressants for major depressive disorders across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as "regions"). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in China. For each major city in question, the percent share the city is of the region and of China is reported. Each major city is defined as an area of "economic population", as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits; this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this "economic" definition of population, comparative benchmarks allow the reader to quickly gauge a city's marketing and distribution value vis-à-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for antidepressants for major depressive disorders. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of antidepressants for major depressive disorders as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Allergan, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck, Merck & Company, Otsuka America Pharmaceutical, Pfizer, Takeda Pharmaceutical Company, and Teva Pharmaceutical Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).
Product Specifications
- Format
- paperback
- ASIN
- B0BBK14958
- Category
- Books > Subjects
- Domain
- Amazon UK
- Release Date
- 16 August 2022
- Listed Since
- 24 August 2022
Similar Products You Might Like
99% match
The 2023-2028 Outlook for Antidepressants for Major Depressive Disorders in the United States
£520.00
25 Aug 2026
99% match
The 2023-2028 Outlook for Antidepressants for Major Depressive Disorders for US Zip Codes
£490.00
20 Oct 2026
98% match
The 2021-2026 World Outlook for Antidepressants
£795.00
12 Aug 2026
98% match
The 2026-2031 World Outlook for Antidepressant Drugs
£885.00
15 Aug 2026
98% match
The 2026-2031 World Outlook for Antidepressants
£885.00
15 Aug 2026
98% match
The 2026-2031 World Outlook for Antidepressant Pharmaceuticals
£885.00
26 Sep 2026
98% match
The 2016-2021 Outlook for Antidepressant Pharmaceuticals in Japan
£595.00
10 Sep 2026
98% match
The 2021-2026 World Outlook for Major Depressive Disorder (MDD) Therapeutics
Price unavailable
98% match
The 2026-2031 World Outlook for Antidepressant and Anti-Anxiety Drugs
£885.00
15 Aug 2026
98% match
The 2023-2028 Outlook for Antidepressants for Anxiety Disorders in the United States
£520.00
25 Aug 2026
97% match
The 2026-2031 World Outlook for Antidepressants for Anxiety Disorders
£885.00
19 Aug 2026
97% match
The 2023-2028 Outlook for Anxiety Disorders and Depression Treatments in the United States
£520.00
23 Aug 2026
97% match
The 2023-2028 Outlook for Anxiety Disorders and Depression in the United States
£520.00
21 Aug 2026
96% match
Diagnostik und Verlauf depressiver Störungen: Differenzierung der Depression - Einbezug von Persönlichkeit und Temperament - multidimensionale Diagnostik
£88.00
07 Sep 2026
96% match
Recent Advances and Challenges in the Treatment of Major Depressive Disorder: 1456 (Advances in Experimental Medicine and Biology, 1456)
Springer
£128.60
03 Sep 2026
96% match
Recent Advances in Depression: Complications, Awareness, and Management: (Mental Illnesses and Treatments Series)
Nova
Price unavailable
96% match
The 2026-2031 World Outlook for Antidepressants for Major Depressive Disorders
£885.00
14 Aug 2026
96% match
Prevention and Early Treatment of Depression Through the Life Course (Depression and Personality)
Springer
£43.96
26 Sep 2026
96% match
Antidepressants: Perspectives, Medical Uses & Health Implications (Pharmacology - Research, Safety Testing and Regualtion)
£100.99
22 Sep 2026
96% match
Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation
Elsevier
£135.69
23 Sep 2026
96% match
Major Depressive Disorder: Rethinking and Understanding Recent Discoveries: 1305 (Advances in Experimental Medicine and Biology, 1305)
Springer
£150.00
18 Oct 2026
96% match
Depressive Disorders in Children and Adolescents: Epidemiology, Risk Factors and Treatment
Jason Aronson
£61.69
17 Oct 2026
96% match
Translational Research Methods for Major Depressive Disorder: 179 (Neuromethods, 179)
Humana
£170.00
27 Aug 2026
96% match
APA Handbook of Depression: Volume 1: Classification, Co-Occurring Conditions, and Etiological Processes; Volume 2: Minoritized Populations, Lifespan ... (APA Handbooks in Psychology® Series)
American Psychological Association
£345.65
22 Aug 2026